SG11202012029PA - Methods and compositions for inhibition of dihydroorotate dehydrogenase - Google Patents

Methods and compositions for inhibition of dihydroorotate dehydrogenase

Info

Publication number
SG11202012029PA
SG11202012029PA SG11202012029PA SG11202012029PA SG11202012029PA SG 11202012029P A SG11202012029P A SG 11202012029PA SG 11202012029P A SG11202012029P A SG 11202012029PA SG 11202012029P A SG11202012029P A SG 11202012029PA SG 11202012029P A SG11202012029P A SG 11202012029PA
Authority
SG
Singapore
Prior art keywords
inhibition
compositions
methods
dihydroorotate dehydrogenase
dihydroorotate
Prior art date
Application number
SG11202012029PA
Inventor
John C Byrd
Thomas E Goodwin
Ola Elgamal
Erin Hertlein
Mouad Abdulrahim
Chad E Bennett
Sandip Madhukar Vibhute
Original Assignee
Ohio State Innovation Foundation
Hendrix College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation, Hendrix College filed Critical Ohio State Innovation Foundation
Publication of SG11202012029PA publication Critical patent/SG11202012029PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11202012029PA 2018-06-22 2019-06-22 Methods and compositions for inhibition of dihydroorotate dehydrogenase SG11202012029PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862688612P 2018-06-22 2018-06-22
PCT/US2019/038622 WO2019246603A1 (en) 2018-06-22 2019-06-22 Methods and compositions for inhibition of dihydroorotate dehydrogenase

Publications (1)

Publication Number Publication Date
SG11202012029PA true SG11202012029PA (en) 2021-01-28

Family

ID=68984309

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202012029PA SG11202012029PA (en) 2018-06-22 2019-06-22 Methods and compositions for inhibition of dihydroorotate dehydrogenase

Country Status (13)

Country Link
US (1) US11312686B2 (en)
EP (1) EP3793562A4 (en)
JP (1) JP7373170B2 (en)
KR (1) KR20210048483A (en)
CN (1) CN112672744B (en)
AU (2) AU2019288813B2 (en)
BR (1) BR112020026308A2 (en)
CA (1) CA3103557A1 (en)
IL (1) IL279586B (en)
MX (1) MX2021000143A (en)
SG (1) SG11202012029PA (en)
WO (1) WO2019246603A1 (en)
ZA (1) ZA202007620B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230303710A1 (en) * 2019-12-26 2023-09-28 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd38 therapeutic agent
EP4081215A4 (en) * 2019-12-26 2024-01-10 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase
JP2023518419A (en) * 2020-03-20 2023-05-01 クリア クリーク バイオ, インコーポレイテッド Stable polymorphic compositions of brequinal sodium and methods of use and preparation thereof
WO2023091793A1 (en) * 2021-11-22 2023-05-25 Ohio State Innovation Foundation Methods and compositions for targeting alternative metabolism along with flt3 inhibitor-mediated antileukemic actions
CN115532290B (en) * 2022-10-13 2024-04-30 浙江昌海制药有限公司 Specific crystal face selective hydrogenation catalyst and preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997042953A1 (en) * 1996-05-10 1997-11-20 Novartis Ag Use of brequinar and derivatives in chronic rejection of allografts and xenotransplantation
JP2003510352A (en) 1999-10-01 2003-03-18 インスティチュート オブ モレキュラー アンド セル バイオロジー Compounds for the treatment of virus-borne diseases
ME00055B (en) 2002-05-17 2010-10-10 Aventis Pharma Sa Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
AU2014209107B2 (en) * 2013-01-28 2018-04-12 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds

Also Published As

Publication number Publication date
CN112672744A (en) 2021-04-16
BR112020026308A2 (en) 2021-03-30
AU2019288813B2 (en) 2023-06-29
IL279586A (en) 2021-01-31
AU2023233065A1 (en) 2023-10-05
CN112672744B (en) 2022-10-14
JP7373170B2 (en) 2023-11-02
US20220064119A1 (en) 2022-03-03
ZA202007620B (en) 2023-02-22
KR20210048483A (en) 2021-05-03
CA3103557A1 (en) 2019-12-26
EP3793562A1 (en) 2021-03-24
JP2021530559A (en) 2021-11-11
IL279586B (en) 2021-09-30
MX2021000143A (en) 2021-08-05
AU2019288813A1 (en) 2021-01-07
US11312686B2 (en) 2022-04-26
WO2019246603A1 (en) 2019-12-26
EP3793562A4 (en) 2021-07-07
US20210253531A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
IL268895A (en) Compositions and methods for inhibition of lineage specific proteins
IL279586B (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase
IL273875A (en) Methods and compositions for inhibiting expression of ldha
EP3573623A4 (en) Compositions and methods for inhibition of factor xii gene expression
IL281939A (en) Inhibitors of vap-1
IL283592A (en) Inhibitors of apol1 and methods of using same
IL284853A (en) Compositions and methods for inhibition of lineage specific antigens
IL287268A (en) Dihydroorotate dehydrogenase inhibitors
IL284989A (en) Dihydroorotate dehydrogenase inhibitors
IL284537A (en) Dihydroorotate dehydrogenase inhibitors
IL287973A (en) Acss2 inhibitors and methods of use thereof
ZA202100780B (en) Bismuth-thiol compositions and methods of use
IL276135A (en) Compositions and methods of use
GB202105087D0 (en) Microbial compositions and methods of use
EP3768301A4 (en) Compositions and methods of fas inhibition
IL281815A (en) Inhibitors of vap-1
EP3555079A4 (en) Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof
EP3841114A4 (en) Methods and compositions for rna expression of myc inhibitors
EP3526221A4 (en) Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof
EP4081215A4 (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase
EP3687514A4 (en) Methods and compositions for inhibition of stat3
EP3773579A4 (en) Compositions and methods for inhibiting dihydroorotate dehydrogenase
IL287797A (en) Oligosaccharide compositions and methods of use
GB201919385D0 (en) Compositions and methods of manufacture
EP3658563A4 (en) Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof